85 related articles for article (PubMed ID: 22399604)
1. The expression of CD146 predicts a poor overall survival in patients with adenocarcinoma of the lung.
Oka S; Uramoto H; Chikaishi Y; Tanaka F
Anticancer Res; 2012 Mar; 32(3):861-4. PubMed ID: 22399604
[TBL] [Abstract][Full Text] [Related]
2. The expression of Ki-67, but not proliferating cell nuclear antigen, predicts poor disease free survival in patients with adenocarcinoma of the lung.
Oka S; Uramoto H; Shimokawa H; Iwanami T; Tanaka F
Anticancer Res; 2011 Dec; 31(12):4277-82. PubMed ID: 22199292
[TBL] [Abstract][Full Text] [Related]
3. The EMT status in the primary tumor does not predict postoperative recurrence or disease-free survival in lung adenocarcinoma.
Chikaishi Y; Uramoto H; Tanaka F
Anticancer Res; 2011 Dec; 31(12):4451-6. PubMed ID: 22199314
[TBL] [Abstract][Full Text] [Related]
4. CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung.
Kwon MS; Shin SH; Yim SH; Lee KY; Kang HM; Kim TM; Chung YJ
Lung Cancer; 2007 Jul; 57(1):46-53. PubMed ID: 17350713
[TBL] [Abstract][Full Text] [Related]
5. Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung.
Ikehara M; Oshita F; Kameda Y; Ito H; Ohgane N; Suzuki R; Saito H; Yamada K; Noda K; Mitsuda A
Oncol Rep; 2002; 9(4):835-8. PubMed ID: 12066218
[TBL] [Abstract][Full Text] [Related]
6. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases.
Kaira K; Oriuchi N; Imai H; Shimizu K; Yanagitani N; Sunaga N; Hisada T; Kawashima O; Kamide Y; Ishizuka T; Kanai Y; Nakajima T; Mori M
Ann Surg Oncol; 2009 Dec; 16(12):3473-81. PubMed ID: 19777189
[TBL] [Abstract][Full Text] [Related]
7. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
[TBL] [Abstract][Full Text] [Related]
8. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.
Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Uchida Y
Cancer; 2003 Jan; 97(2):457-64. PubMed ID: 12518370
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma.
Wang R; Geng J; Wang JH; Chu XY; Geng HC; Chen LB
Lung Cancer; 2009 Nov; 66(2):237-44. PubMed ID: 19261348
[TBL] [Abstract][Full Text] [Related]
12. Expression of dysadherin and cytokeratin as prognostic indicators of disease-free survival in patients with stage I NSCLC.
Ono K; Uramoto H; Hanagiri T
Anticancer Res; 2010 Sep; 30(9):3273-8. PubMed ID: 20944097
[TBL] [Abstract][Full Text] [Related]
13. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
Grah J; Samija M; Juretić A; Sarcević B; Sobat H
Coll Antropol; 2008 Sep; 32(3):731-6. PubMed ID: 18982744
[TBL] [Abstract][Full Text] [Related]
14. Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung.
Kamimura A; Kamachi M; Nishihira J; Ogura S; Isobe H; Dosaka-Akita H; Ogata A; Shindoh M; Ohbuchi T; Kawakami Y
Cancer; 2000 Jul; 89(2):334-41. PubMed ID: 10918163
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of integrin β1, E-cadherin, and rac1 expression in small cell lung cancer.
Chang MH; Lee K; Lee KY; Kim YS; Kim YK; Kang JH
APMIS; 2012 Jan; 120(1):28-38. PubMed ID: 22151306
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer.
Soltermann A; Tischler V; Arbogast S; Braun J; Probst-Hensch N; Weder W; Moch H; Kristiansen G
Clin Cancer Res; 2008 Nov; 14(22):7430-7. PubMed ID: 19010860
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
18. Expression of the p53 family in lung cancer.
Uramoto H; Sugio K; Oyama T; Nakata S; Ono K; Nozoe T; Yasumoto K
Anticancer Res; 2006; 26(3A):1785-90. PubMed ID: 16827107
[TBL] [Abstract][Full Text] [Related]
19. Clinical implication and prognostic significance of the tumor suppressor TSLC1 gene detected in adenocarcinoma of the lung.
Uchino K; Ito A; Wakayama T; Koma Y; Okada T; Ohbayashi C; Iseki S; Kitamura Y; Tsubota N; Okita Y; Okada M
Cancer; 2003 Sep; 98(5):1002-7. PubMed ID: 12942568
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
